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OBJECTIVE — Our objectives were to determine the prevalence of previously undiagnosed
abnormal glucose tolerance, i.e., diabetes and impaired glucose tolerance (IGT) in patients with
acute coronary syndrome and to assess the utility of admission and fasting glucose in identifying
diabetes in these patients.
RESEARCH DESIGN AND METHODS — Glycemic status was characterized on the
basis of admission plasma glucose (APG), fasting plasma glucose (FPG), and an oral glucose
tolerance test (OGTT) in 140 patients admitted to the hospital with acute coronary syndrome,
who were not known to have diabetes (mean  SD age 67.3  13.4 years; 79% men). OGTTs
were performed on days 5–7 after admission.
RESULTS — The prevalences of diabetes and IGT were 27 and 39%, respectively, according
to OGTT criteria. Receiver operating characteristic curves showed that the area under the curve
for diagnosing diabetes was 0.83 (P  0.001) for FPG, 0.79 (P  0.001) for APG, and 0.84 (P 
0.001)forFPGandAPGappliedincombination.AFPGcutoff5.6mmol/l(100mg/dl)and/or
APG 7.8 mmol/l (140 mg/dl) yielded a sensitivity of 89.5% and a positive predictive value of
43.6% for detecting diabetes.
CONCLUSIONS — A high prevalence of abnormal glucose tolerance was seen in patients
with acute coronary syndrome. The combination of FPG 5.6 mmol/l (100 mg/dl) and/or APG
7.8mmol/l(140mg/dl)washighlysensitiveforidentifyingdiabetes.Althoughweaklyspeciﬁc,
this simple algorithm could offer a practical initial screening tool at the acute setting in the
high-risk population with acute coronary syndrome.
Diabetes Care 31:1955–1959, 2008
D
iabetes is associated with increased
cardiovascular risk. Individuals
withdiabeteshaveagreatermortal-
ity from acute myocardial infarction
(AMI) than nondiabetic individuals (1).
After an acute coronary event, hypergly-
cemiahasbeenshowntobeapredictorof
immediate and long-term cardiovascular
mortality (2). Although the prevalence of
diabetes has continued to rise, diabetes
remainsundiagnosedinmanypatients.In
recent years several studies have reported
an increased prevalence of prior undiag-
nosed abnormal glucose tolerance, i.e.,
impaired glucose tolerance (IGT) and
diabetes in patients with AMI (3–6).
Furthermore, such newly diagnosed ab-
normalities of glucose metabolism have
been shown to be associated with an ex-
cess long-term cardiovascular mortality
(7). Thus, patients with acute coronary
syndrome present an opportunity for
targeted screening for diabetes and
institution of effective management strat-
egies aimed to improve cardiovascular
outcome.
The optimal strategy for identifying
individuals with diabetes in the setting of
an acute coronary syndrome is unclear,
however. Although the oral glucose toler-
ance test (OGTT) is considered the gold
standard for the diagnosis of diabetes, its
utility is hampered by its cost, time-
consumingprotocol,andoverallinconve-
nience compared with simple fasting or
admission glucose measurements. Ac-
cordingly, clinicians in practice often
adopt the more pragmatic approach of
characterizing glycemic status on the ba-
sis of admission and fasting glucose val-
ues. The Joint British Societies’ 2005
clinical guidelines on prevention of car-
diovascular disease recommended that a
fasting glucose measurement can be done
as an alternative to an OGTT in patients
who have had an acute cardiovascular
event(8).However,thereisincreasingev-
idence to suggest that use of fasting glu-
cose measurements alone will miss a
substantialproportionofpatientswithdi-
abetes after an AMI (4). Studies speciﬁ-
callyaddressingthisissueinthesettingof
the full spectrum of the acute coronary
syndrome are limited. Likewise, the diag-
nostic utility of admission glucose mea-
surements in patients with coronary
events has received little attention even
though hyperglycemia in this setting
could potentially represent preexisting
undiagnosed diabetes.
Thus, it remains unresolved whether
an OGTT is mandatory after an acute cor-
onary syndrome or whether admission
andfastingglucosecouldeffectivelyiden-
tify patients with diabetes or at the least
stratify individuals who will merit an
OGTT. Our objective in this study was
ﬁrst to clarify the prevalence of unrecog-
nized abnormal glucose tolerance in our
own population of patients with acute
coronary syndrome in South Wales,
U.K. Second, we analyzed the perfor-
mance of fasting and admission glucose
measurements, applied individually or in
combination, as markers of previously
undiagnosed diabetes in patients with
acute coronary syndrome.
RESEARCH DESIGN AND
METHODS— We studied 140 pa-
tientswhowereadmittedconsecutivelyto
our coronary care unit with a diagnosis of
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patients with previously known diabetes
or IGT. Clinical and demographic data
were obtained for each patient including
blood pressure, lipid proﬁle, and BMI. A
casualbloodglucosesamplewastakenon
the day of admission, usually on arrival to
the coronary care or emergency unit.
When more than one admission glucose
level was available, the highest reading
was selected for analysis. A standardized
75-g OGTT was performed before dis-
charge, usually between days 5 and 7.
This was performed in the morning, after
a 12-h overnight fast according to the
World Health Organization protocol (9).
Laboratory analysis
Blood samples were separated within 30
min of collection and centrifuged (2000g
for5min)at4°C,andplasmaglucosewas
assayed by an automated glucose oxidase
method. Total cholesterol and triglycer-
ideswerealsoanalyzedinfastingsamples.
Cardiac troponin T was measured on ad-
missionandatleast12haftertheprimary
clinical event.
Deﬁnitions
Glycemicstatuswasclassiﬁedonthebasis
of the 2-h postload (2-h plasma glucose)
glucose values of the OGTT according to
the World Health Organization 1998 def-
initions(9)asfollows:normalglucosetol-
erance (NGT), 7.8 mmol/l (140 mg/dl);
IGT, 7.8–11.0 mmol/l (140–200 mg/dl);
and diabetes, 11.1 mmol/l (200 mg/dl).
Patients were also stratiﬁed according to
fasting plasma glucose (FPG) on the basis
of the American Diabetes Association
2004 criteria (10). The cutoff limits for
FPG were 5.6 mmol/l (100 mg/dl) for
NGT, 5.6–6.9 mmol/l (100–125 mg/dl)
for impaired fasting glucose (IFG), and 
7.0 mmol/l (126 mg/dl) for diabetes. Ad-
mission plasma glucose (APG) was strati-
ﬁed into three groups: 7.8 mmol/l (140
mg/dl), 7.8–11.0 mmol/l (140–200 mg/
dl), and 11.1 mmol/l (200 mg/dl).
The diagnosis of AMI was based on
the joint recommendations by the Euro-
pean Society of Cardiology and American
College of Cardiology (11). AMI was di-
agnosed if there was a typical rise and
gradual fall in the levels of cardiac tro-
ponins with at least one of the following
features: typical ischemic cardiac chest
pain and compatible electrocardiograph
changes of myocardial infarction or isch-
emia. Unstable angina was diagnosed if
patients had cardiac chest pain either at
rest, of new onset, or of an accelerating
nature, accompanied by electrocardio-
graph changes of ischemia and negative
results for cardiac troponins (12).
Statistical analysis
Values are presented as means  SD ex-
ceptwhereotherwisestated.Allstatistical
analysis was performed using SPSS for
Windows (version 12.0; SPSS, Chicago,
IL). Characteristics of patients in the dif-
ferent glycemic groups were compared
using the 
2 test for categorical data or
ANOVAforcontinuousdatawithTukey’s
post hoc procedure applied for multiple
group comparisons. The relationship be-
tween different measurements of plasma
glucosewasexaminedwithPearson’scor-
relation coefﬁcients. We determined the
sensitivity, speciﬁcity, and positive pre-
dictive values (PPVs) for fasting and
admission glucose. Sensitivity was calcu-
lated as the percentage of patients with
diabetes who had a FPG or APG value
greater than the designated cutoff point.
Speciﬁcity was the percentage of patients
without diabetes who had FPG or APG
values below the chosen cutoff point. We
generated receiver operating characteris-
tic (ROC) curves to determine the accu-
racy of FPG and APG values as indicators
of diabetes. An area under the ROC curve
(AUC) was calculated for each indicator,
andtheoptimalcutoffpointforthedetec-
tion of diabetes was estimated from the
ROC. The level of statistical signiﬁcance
at which the null hypothesis was rejected
was chosen as 0.05.
RESULTS— The baseline characteris-
tics of the patients according to OGTT
status are shown in Table 1. There were
no signiﬁcant differences in age, sex, and
ethnic distribution between the various
categories of glucose tolerance. The prev-
alence of undiagnosed IGT and diabetes
was higher in patients with AMI than in
Table 1—Clinical and laboratory characteristics of patients classiﬁed according to an OGTT
Clinical characteristics
OGTT classiﬁcation
P NGT IGT Diabetes
n (%) 48 (34) 54 (39) 38 (27)
Age (years) 65.7  14.1 67.6  13.7 69.0  13.4 0.5
Sex (% male) 81.0 80.0 76.0 0.8
Ethnicity (%) 0.9
White 94.0 92.0 92.0
Other* 6.0 8.0 8.0
Cardiac diagnosis (%) 0.002†
AMI 29.0 57.0 63.0
Unstable angina 71.0 43.0 37.0
BMI (kg/m
2) 26.8  2.9 28.2  3.2 27.3  3.2 0.08
Systolic blood pressure (mmHg) 134  22.5 134  15.4 135  19.0 0.86
Diastolic blood pressure (mmHg) 82  15.7 77  10.1 83  10.7 0.09
Laboratory variables
Cholesterol (mmol/l) 4.4  0.8 4.2  0.8 4.6  1.1 0.66
Triglyceride (mmol/l) 1.4  0.7 1.5  0.5 1.7  0.9 0.58
APG (mmol/l) 6.6  1.6 (4.2–13.4) 6.9  1.6 (3.4–13.3) 9.3  3.5 (5.2–19.7) 0.001‡
Fasting plasma glucose (mmol/l) 5.1  0.5 (4.0–6.8) 5.6  0.6 (4.2–6.9) 6.8  1.4 (4.7–10) 0.001§
Data are n (%), means  SD, or means  SD (range). *Includes patients of south Asian and Afro-Caribbean ethnicity. †Diabetes vs. NGT; IGT vs. NGT. ‡Diabetes
vs. IGT; diabetes vs. NGT. §Diabetes vs. IGT; diabetes vs. NGT; IGT vs. NGT.
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pressure, total cholesterol, and triglycer-
ide levels were not statistically signiﬁ-
cantly different between the three
different glycemic categories. FPG levels
differed between all three groups,
whereas the APG level was higher in dia-
betic patients than in the other groups
(Table 1).
Prevalence of abnormal glucose
tolerance
The prevalences of diabetes and IGT on
the basis of the OGTT were 27 and 39%,
respectively.Ofthepatientswithdiabetes
according to the OGTT, 14 (37%) had
FPG7.0mmol/l(126mg/dl),whereas6
(16%) had APG 11.1 mmol/l (200 mg/
dl). Figure 1 shows the prevalence of di-
abetes at various cutoff points for FPG
and APG.
Performance of APG and FPG
measurements
The sensitivities, speciﬁcities, and PPVs
for diagnosing diabetes with FPG and
APG are shown in Table 2. FPG was more
sensitive but less speciﬁc than APG in de-
tectingdiabetes.Thecombinationofboth
criteria led to improved sensitivity but
had poor speciﬁcity and PPV (Table 2).
UsingthedualFPGandAPGcutoffpoints
of FPG 5.6 mmol/l (100 mg/dl) and/or
APG 7.8 mmol/l (140 mg/dl) as thresh-
oldsforperforminganOGTTwouldhave
yielded a sensitivity of 89.5% and would
have reduced the number of OGTTs per-
formed to 52% of patients.
The AUCs for diagnosing diabetes
were0.83(P0.001)forFPG,0.79(P
0.001) for APG, and 0.84 (P  0.001) for
FPG and APG applied in combination.
The diagnostic performance of FPG and
APG measurements did not differ when
patients were stratiﬁed according to car-
diac diagnosis. The AUC was similar in
patientswithAMIandunstableanginafor
each of the diagnostic indexes. For FPG,
the AUCs were 0.834 and 0.823 in pa-
tients with AMI and unstable angina, re-
spectively, whereas the AUCs for APG
were 0.794 and 0.746, respectively. The
AUCs for combined FPG and APG were
0.851 in patients with AMIs and 0.804 in
patients with unstable angina. The opti-
mal cutoff point for diagnosing diabetes
with FPG was 5.8 mmol/l (104.4 mg/dl).
This is the FPG value with the best sensi-
tivityandspeciﬁcityforidentifyingdiabe-
tes in this setup. At this cutoff, the
sensitivity and speciﬁcity of FPG in de-
tecting diabetes were 69.2 and 77.2%, re-
spectively. The optimal cutoff point for
identifying diabetes with APG was
7.7mmol/l (138.6 mg/dl); this cutoff
point was associated with sensitivity of
65.8% and speciﬁcity of 82.4%.
We determined the relationship be-
tween 2-h postload glucose and admis-
sion and FPG using the Pearson’s
correlation coefﬁcients. FPG showed a
better correlation to 2-h plasma glucose
(r  0.56; P  0.0001) than APG (r 
0.38; P  0.0001).
CONCLUSIONS — We determined
the prevalence of hitherto undiagnosed
glycemic abnormalities in patients pre-
senting with acute coronary syndrome in
our institution. Two-thirds of patients
had abnormal glucose tolerance on an
OGTT, comprising diabetes (27%) and
IGT (39%). The high prevalence of glyce-
mic abnormalities in our U.K. sample is
consistent with reports from elsewhere.
Norhammar et al. (3) observed that 35%
of Swedish patients with AMI had undi-
agnosed IGT, whereas 31% had diabetes.
Their ﬁndings were subsequently con-
ﬁrmed in a large multicenter European
survey, which showed a prevalence of
36% for IGT and 22% for diabetes in 923
patients with acute coronary artery dis-
ease and no previous dysglycemia (4).
High rates of newly detected glycemic ab-
normalities have similarly been reported
in other populations with acute coronary
syndrome (5,6).
APG or FPG measurements alone un-
derestimatedtheprevalenceofdiabetesin
our study. This ﬁnding is in keeping with
the experience of others who have shown
that glycemic status in the acute coronary
Table 2—Performance of FPG and APG in the diagnosis of diabetes in patients with acute
coronary syndrome
Prevalence Sensitivity Speciﬁcity PPV
FPG 5.6 mmol/l 48 81.6 64.7 46.3
APG 7.8 mmol/l 30 65.8 83.3 59.5
FPG 5.6 or APG 7.8 mmol/l 52 89.5 56.9 43.6
Data are percent.
Figure 1—Prevalence of diabetes (according to an OGTT) at various cutoff points for FPG (A) and APG (B).
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byFPG(4,5,13)orAPG(14).Application
of the diabetes cutoff points for FPG and
random glucose measurements would
have missed the majority of diabetic pa-
tients. However, lower cutoff values for
FPGandAPGmeasurementswereassoci-
ated with better sensitivity. Using the IFG
cutoff of 5.6 mmol/l (100 mg/dl) as a
threshold for performing OGTTs yielded
acceptable sensitivity and would have re-
duced the proportion of OGTTs required
to46%.TheoptimalFPGthresholdof5.8
mmol/l (104.4 mg/dl) would have further
reduced the number of required OGTTs
but was not sufﬁciently sensitive for
screening purposes. Combining the IFG
threshold with an APG cutoff of 7.8
mmol/l (140 mg/dl) offered the best sen-
sitivity for detecting diabetes, missing
only 10% of diabetic patients but requir-
ing OGTTs to be performed in 52% of
patients with acute coronary syndrome.
Thus, FPG and APG proved useful as
early markers of diabetes in our patients
with acute coronary syndrome, including
patients with AMI as well as those with
unstable angina.
The increased frequency of undiag-
nosed diabetes and IGT observed in our
patients is signiﬁcant in the light of evi-
dence showing that newly diagnosed ab-
normal glucose tolerance in patients with
acute coronary syndrome is a strong pre-
dictor of future cardiovascular mortality
(7). In the Funagata Diabetes Study in Ja-
pan, IGT was found to be a risk factor for
cardiovascular mortality (15). In addi-
tion, IGT appears to be an intermediate
step in the development of diabetes. In a
study of 1,342 subjects in a Dutch popu-
lation, the cumulative incidence of diabe-
tes after a mean follow-up period of 6.4
years was 64.5% in patients with IGT
compared with 4.5% for those with NGT
at baseline (16). More importantly, it ap-
pears that this progression can be effec-
tively delayed by the implementation of
pharmacological and nonpharmacologi-
cal measures such as dietary adjustments
and increased physical activity. In 3,234
individuals with elevated but nondiabetic
fasting and postload glucose levels, life-
style modiﬁcation and treatment with
metformin were individually more effec-
tive than placebo in reducing the inci-
dence of diabetes (17).
Therefore, it seems prudent to iden-
tify patients with glycemic abnormalities
at the earliest possible opportunity and
initiate appropriate management of their
cardiometabolic risks. The OGTT re-
mains the gold standard for early detec-
tion of glycemic abnormalities but
continues to be underused in clinical
practice. In the Euro Heart Survey, which
involved4,000participantsin25Euro-
pean countries, an OGTT was not per-
formed in 50% of patients with stable
and acute coronary heart disease (13). A
reluctance to perform OGTTs may reﬂect
prevailing local policies as well as the in-
dividual preferences of clinicians in acute
care settings, who may opt for more prac-
tical algorithms on the basis of FPG and
random glucose values. Our results indi-
cate that FPG or APG alone will underes-
timate the prevalence of diabetes but may
be useful in selecting patients for an
OGTT, thereby limiting the amount of
glucose tolerance tests performed. How-
ever, using FPG or random glucose
thresholds for performance of OGTTs
would still require a considerable per-
centage of OGTTs and would inevitably
miss a fraction of patients with diabetes
and IGT.
One limitation of our study is that
OGTTs were performed on a single occa-
sion during hospital admission. It could
be argued that such tests were inﬂuenced
by acute stress. However, a recent study
by the European Heart Survey group
showed that OGTTs done in the hospital
within 4–5 days after an acute coronary
syndrome correlated well with glycemic
status at 3 and at 12 months (18). At
present there appears to be no consensus
on the timing of OGTTs after acute coro-
narysyndrome;inclinicalstudiesthishas
ranged from 3 to 7 days after a coronary
event (4–6,14). Studies are required to
clarify the optimal performance condi-
tions for glucose tolerance testing after an
acute coronary syndrome. A pragmatic
approachwouldbetoreevaluateglycemic
status in an outpatient setting at least 2
monthsafterdischargewhentheeffectsof
acute stress would have subsided. The
feasibility of a two-step protocol in which
further testing in the outpatient setting is
performed in patients with elevated ad-
missionfasting(5.6mmol/l;100mg/dl)
or random glucose (7.8 mmol/l; 140
mg/dl) concentrations deserves further
evaluation.
In summary, we observed a high
prevalence of abnormal glucose tolerance
in our patients with acute coronary syn-
drome.ThecombinationofFPGandAPG
measurements was highly sensitive in
identifying patients with diabetes. These
simple measurements are readily avail-
able in the acute setting and could form a
useful initial screening tool in this patient
population with high rates of undiag-
nosed diabetes.
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